Document is current
Any future updates will be listed below
-
Authors
Bundo, Marvin
Preisig, Martin
Merikangas, Kathleen
Glaus, Jennifer
Vaucher, Julien
Waeber, Gérard
Marques-Vidal, Pedro
Strippoli, Marie-Pierre F.
Müller, Thomas
Franco, Oscar
Vicedo-Cabrera, Ana Maria
-
Funding
Funding for this research was provided by:
European Union’s Horizon 2020 research and innovation programme (801076)
GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (3200B0–105993, 3200B0-118308, 33CSCO-122661, 33CS30-139468, 33CS30-148401, 33CS30_177535 and 3247730_204523)
GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (3200B0–105993, 3200B0-118308, 33CSCO-122661, 33CS30-139468, 33CS30-148401, 33CS30_177535 and 3247730_204523)
GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (3200B0–105993, 3200B0-118308, 33CSCO-122661, 33CS30-139468, 33CS30-148401, 33CS30_177535 and 3247730_204523)
GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (3200B0–105993, 3200B0-118308, 33CSCO-122661, 33CS30-139468, 33CS30-148401, 33CS30_177535 and 3247730_204523)
GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (3200B0–105993, 3200B0-118308, 33CSCO-122661, 33CS30-139468, 33CS30-148401, 33CS30_177535 and 3247730_204523)
GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (3200B0–105993, 3200B0-118308, 33CSCO-122661, 33CS30-139468, 33CS30-148401, 33CS30_177535 and 3247730_204523)
Swiss Personalized Health Network (2018DRI01)
Swiss Personalized Health Network (2018DRI01)
Swiss Personalized Health Network (2018DRI01)
Swiss Personalized Health Network (2018DRI01)
Swiss Personalized Health Network (2018DRI01)
Swiss Personalized Health Network (2018DRI01)
- License Information
-
More Information
Article History
Received: 22 March 2023
Accepted: 28 June 2023
First Online: 11 July 2023
Declarations
:
: The institutional Ethics Committee of the University of Lausanne, which afterwards became the Ethics Commission of the Canton of Vaud () approved the baseline CoLaus|PsyColaus study (reference 16/03; 134-03,134-05bis, 134-05-2to5 addenda 1to4). The approval was renewed for the first (reference 33/09;239/09), the second (reference 26/14; 239/09 addendum 2), the third (PB_2018-00040; 239/09 addenda 3to4) and the fourth (PB_2018_0038 (239/09)) follow-ups. The study was performed in agreement with the Helsinki declaration and its former amendments, and in accordance with the applicable Swiss legislation. All participants signed a written informed consent.
